|
|
|
|
|
|
|
Prostate Cancer and Prostatic Diseases |
|
|
|
|
| Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer in a Prospective Statewide Collaborative - Full-Text Article
|
| Randy A. Vince Jr., Ralph Jiang, Ji Qi, Jeffrey J. Tosoian, Rebecca Takele, Felix Y. Feng, Susan Linsell, Anna Johnson, Sughand Shetty, Patrick Hurley, David C. Miller, Arvin George, Khurshid Ghani, Fionna Sun, Mariana Seymore, Robert T. Dess, William C. Jackson, Matthew Schipper, Daniel E. Spratt, and Todd M. Morgan
|
| A multi-institutional study of 855 men who underwent Decipher Biopsy testing between February 2015 and October 2019. All patients were tracked through the prospective Michigan Urological Surgery Improvement Collaborative and linked to the Decipher Genomics Resource Information Database. This study sought to assess the clinical utility of Decipher Biopsy in localized prostate cancer patients.
|
|
|
|
|
|
| Real-World Clinical Utility of Decipher Biopsy Testing in Localized Prostate Cancer - Editorial
|
| Jack Schalken, Ph.D.
|
| In prostate pre- and post-biopsy decision making, more precision is urgently needed. Whereas expert imaging and biomarker-based risk scores already enable the clinician in this respect, the dilemma remains for those patients that are diagnosed with apparent indolent cancer. Additional diagnostic tools that (de)select patients for active surveillance (AS) would provide a great benefit for the patient.
|
|
|
|
|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial
|
Daniel Spratt, MD and Alan Dal Pra, MD
In this UroToday presentation, Daniel Spratt and Alan Dal Pra share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone therapy with postoperative radiation therapy and the clinical implications for Decipher.
|
|
|
|
|
|
|
|
|
|
|
| Validating the Genomic Classifier to Identify Patients With a High Risk of Metastasis Among African American Men With Early Localized Prostate Cancer, VANDAAM Study |
| Kosj Yamoah, MD, Ph.D. |
| In this conversation with Alicia Morgans, Kosj Yamoah highlights the currently enrolling VANDAAM Study, a prospective study validating the genomic classifier to identify patients with a high risk of metastasis among African American men with early localized prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| Improving the Quality of Care for Men in Michigan With Prostate Cancer, the MUSIC Collaborative, a Focus on the G-MINOR and G-MAJOR Trials |
| Todd Morgan, MD, Ph.D. |
| In this conversation, Todd Morgan joins Mathew Cooperberg highlighting the success and current initiatives of the Michigan Urological Surgery Improvement Collaborative (MUSIC), program. |
|
|
|
|
|
|
|
|
|
|
|
| Validation of a 22-Gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413, and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer
|
| Paul Nguyen, MD
|
| Paul Nguyen provides a discussion regarding the validation of a 22-gene genomic classifier in the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials. This is the first validation of any gene expression biomarker on pre-treatment biopsy samples from prospective randomized trials and demonstrates an independent association of the genomic classifier score with distant metastasis, prostate cancer specific mortality, and overall survival.
|
|
|
|
|
|
|
|
|
|
|
| Incorporating Genomic Testing For Prostate Cancer into Your Practice – Decipher and ProMark at Diagnosis
|
| Joseph Robert Wagner, MD
|
| In anticipation of the 2021 American Urological Association Annual Meeting which was held, in a delayed fashion, in September, the AUA hosted a “May Kick-Off Weekend” which highlighted a variety of important topics in both benign urology and urologic oncology. Joseph Wagner led a course entitled “Incorporating Genomic Testing For Prostate Cancer into Your Practice” along with faculty Daniel Lin and Matthew Cooperberg.
|
|
|
|
|
|
Adjuvant vs. Salvage Radiation Therapy after Radical Prostatectomy: Role of Decipher® in the Era of Personalized Medicine - Beyond the Abstract
|
| Ali Nowroozi, Amirali Karimi, Sanam Alilou, Erfan Amini |
| Prostate cancer is an important subject in global health, with increasing incidence and burden. Radical prostatectomy is the treatment of choice for many patients. However, some cases experience biochemical recurrence (BCR). According to current guidelines, adjuvant radiation therapy is administered to reduce the risk of BCR in patients with adverse pathological features (i.e., locally advanced disease or positive margin). An alternative approach is to start radiation therapy after BCR (salvage radiation therapy). |
|
|
|
|
|
| Biomarkers to Guide Primary and Systemic Treatment for High-Risk Localized Prostate Cancer |
| Felix Feng MD |
| Felix Feng discusses biomarkers to guide primary and systemic therapy for patients with high-risk localized prostate cancer. He sought to cover three main topics: the role of biomarkers in treatment naïve patients, the role of biomarkers following prostatectomy, and the role of germline testing. |
|
|
|
|
|
|
|
|
|
|
|
